NEW YORK (GenomeWeb) – South Korean genomic services provider Macrogen announced today that it has acquired a non-exclusive research tool license to CRISPR-Cas9 technology from the Broad Institute.

Macrogen said that it intends to use the genome-editing technology to build preclinical animal models and for target treatment function analysis to advance precision medicine and gene therapy research and development.

Specific terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.